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ABSTRACT
Recent research has focused on the impact of long noncoding RNA (lncRNA) 
in cervical carcinogenesis. However, whether HOXA11 antisense (HOXA11-AS) 
is involved in cervical cancer remains to be elucidated. In the present study, we 
examined HOXA11-AS expression levels in cervical cancer patients and determined 
the relationships between HOXA11-AS expression and clinicopathological factors. 
We also investigated the bio-functional consequences of HOXA11-AS overexpression 
both in vitro and in vivo. HOXA11-AS expression was significantly greater in tissues 
from patients with cervical cancer than in control patients (P<0.001). Multivariate 
analysis showed that high HOXA11-AS was an independent prognosticator of overall 
survival (Hazard ratio=2.450, P=0.032). HOXA11-AS overexpression enhanced 
cell proliferation, migration, and tumor invasion in vitro, whereas HOXA11-AS 
knockdown inhibited these biologic aggressive features. These adverse changes were 
accompanied by characteristics of epithelial-mesenchymal transition (EMT). In vivo 
xenograft experiments using the siHOXA11-AS-transfected HeLa cells revealed that 
HOXA11-AS strongly induced tumor growth. Furthermore, we found that HOXA11-AS 
knockdown decreased cancer stemness and triggered the EMT program. In conclusion, 
HOXA11-AS overexpression correlated with poor survival in patients with cervical 
cancer. Thus, HOXA11-AS may be a pivotal target for exploring novel cervical cancer 
therapeutics.
INTRODUCTION
Cervical cancer is the third most common cancer 
and the fourth leading cause of malignancy related 
mortality in women worldwide [1]. Although widespread 
implementation of screening programs in recent years has 
decreased the incidence and mortality of this cancer, it 
continues to be a major public health problem, specifically 
in advanced cases [2]. Major research efforts have 
focused on identifying tumor-specific markers predicting 
the biological behavior of cervical cancers, because cell 
motility and invasion are crucial in the progression of 
cancer [3]. An increased understanding of the molecular 
mechanisms underlying cervical carcinogenesis and 
progression is required to identify reliable prognosticators 
of tumor aggressiveness.
Noncoding RNAs (ncRNAs) may be key factors 
in gene regulation, influencing normal and cancer cell 
phenotypes [4, 5]. Over 3000 human long intervening coding 
RNAs (lincRNAs), and most long ncRNAs, are associated 
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with DNA-binding proteins such as chromatin-modifying 
complexes [6] that epigenetically regulate the expression of 
multiple genes [7]. Transcription of long noncoding RNAs 
(lncRNAs) modulates gene activity in response to external 
oncogenic stimuli and DNA damage [8].
Several cancers highly express the homeobox 
A11 antisense lncRNA (HOXA11-AS), which is near 
the homeobox A11 (HOXA11) gene, further supporting 
the model that this lncRNA influences cervical cancer 
progression [9]. Human HOX gene clusters feature 
prevalent intergenic transcription between coding genes 
[10]. Noncoding RNAs seem to dominate homeobox 
gene cluster intergenic transcripts, which include short 
microRNAs (miRNA) and lncRNAs that are antisense to 
their canonical HOX neighbors. In humans and mice, HOX 
transcription factors stimulate embryonic development 
[11]. Homeobox A11 antisense lncRNA transcripts occur 
in the adult human endometrium. The abundance of 
these transcripts varies throughout the menstrual cycle; 
peak antisense RNA levels occur in the midproliferative 
phase, varying inversely with mRNA expression levels. 
In primary stromal cell culture, progesterone down-
regulates HOXA11-AS transcription. This HOXA11-
AS downregulation is followed by HOXA11 mRNA 
upregulation, indicating a possible role for the antisense 
transcript in regulating mRNA expression [12]. The 
mechanism by which HOXA11-AS represses HOXA11 
mRNA is transcriptional interference rather than sense/
antisense interaction; HOXA11-AS represses HOXA11 by 
competing for transcription of a common gene. Homeobox 
A11 DNA methylation prognosticates ovarian cancer 
[13]. Homeobox A11 antisense lncRNA suppresses the 
expression of the HOXA11 gene. Although HOXA11 DNA 
methylation was observed to correlate in the progression 
of ovarian cancer, little is known about the molecular 
mechanisms underlying cervical cancer.
Cancer stem cells (CSCs) are responsible for 
tumor-initiating capacity, invasion, metastasis, relapse, 
and chemotherapy resistance [14]. The presence of 
a small population of CSCs in cervical cancer has 
major implications for cancer therapy and the complete 
eradication of refractory tumors. According to the CSC 
theory, these cells exhibit high levels of resistance to 
multi-drug treatment, as they possess an increased capacity 
for proliferation and DNA repair, and a downregulated 
epithelial-mesenchymal transition (EMT) program [15, 
16]. However, the complex biology of cervical CSCs and 
the underlying pathogenic mechanisms remain unknown. 
Recent studies focus on molecular mechanisms underlying 
cervical CSC progression and new therapies against 
cervical CSCs [17–19].
The present study investigated the expression and 
molecular function of HOXA11-AS in cervical cancer 
cell lines and cancer tissues. We also examined the role 
of HOXA11-AS in tumor progression and CSCs. The 
findings of this study will be useful in elucidating the role 
of HOXA11-AS in the metastatic progression of cervical 
cancer.
RESULTS
Elevated expression of HOXA11-AS correlates 
with poor cervical cancer prognosis
Real time RT-PCR was performed to evaluate 
the expression of HOXA11-AS lncRNA in cervical 
cancer tissues (n=92) and corresponding normal tissues 
(n=30). Homeobox A11 antisense lncRNA expression 
in cervical cancer tissues was more than 227.5-fold that 
of noncancerous tissues (Figure 1A), suggesting that 
the expression of HOXA11-AS is upregulated in cervical 
cancer. We also performed real time RT-PCR assays on 
HOXA11-AS expression levels in six different cell lines, 
one of which was derived from human normal ovarian 
cells (HOSE), and five of which were derived from human 
cervical cancers. We found that HOXA11-AS expression 
levels were higher in epitheloid cervical carcinoma 
(HeLa), epidermoid cervical carcinoma established 
from a metastasis in the small bowel mesentery (CaSki), 
and squamous cervical carcinoma (SiHa) cells than in 
epidermoid cervical carcinoma (ME-180) and HPV 
negative cervical carcinoma (C33A) cells (Figure 1B).
We examined the relationship between HOXA11-
AS expression and clinical outcomes (Table 1). Patients 
with high HOXA11-AS expression presented more 
lymphovascular invasion, lymph node metastasis, and 
recurrence relative to patients with low HOXA11-AS 
expression, but this relationship was not statistically 
significant.
The median overall survival (OS) durations were 
43 and 46.5 months in the high and low HOXA11-
AS expression groups, respectively. The log-rank test 
indicated a significantly longer OS for the low HOXA11-
AS expression group (P=0.009) (Figure 1C). Five-year 
survival rates were 58.3% and 79.9% in high and low 
HOXA11-AS expression groups, respectively. A Cox 
multivariate proportional hazards analysis showed that 
stage (hazard ratio [HR]=3.546, P=0.02), nodal metastasis 
(HR=2.724, p=0.023), and HOXA11-AS (HR=2.450, 
P=0.032) were independent prognosticators of overall 
survival (Table 2).
Knockdown of HOXA11-AS decreases cell 
proliferation in cervical cancer cells
To investigate the functional role of HOXA11-
AS in cervical cancer, siRNA was used to downregulate 
HOXA11-AS expression. HeLa and CaSki cells were 
used for siRNA-mediated knockdown of HOXA11-AS 
expression. The knockdown efficiency of the HOXA11-
AS-specific siRNAs (siHOXA11-AS) was evaluated, 
and siHOXA11-AS was found to have a higher silencing 
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efficiency than the negative control siRNA (Figure 2A). 
We next examined the impact of HOXA11-AS knockdown 
on cell proliferation. The results of the CCK-8 assay 
showed that siRNA-mediated knockdown of HOXA11-
AS in HeLa and CaSki cells decreased cell proliferation 
(Figure 2B), suggesting that HOXA11-AS is involved in 
the proliferation of cervical cancer.
Lentiviral-mediated overexpression or 
knockdown of HOXA11-AS reveals that high 
HOXA11-AS expression promotes cervical cancer 
cell migration and invasion
To determine whether HOXA11-AS increases 
migration and invasion in cervical cancer cells, we 
performed wound healing and Matrigel invasion assays. 
We established stable HOXA11-AS-overexpressed SiHa and 
ME-180 cells by antibiotic selection of a pool of lentivirus-
infected cells (Figure 3A). Overexpression of HOXA11-AS 
resulted in increased migration of SiHa cells relative to 
empty vector-expressing controls (Figure 3B). In contrast, 
siRNA-mediated knockdown of HOXA11-AS inhibited 
cell migration in HeLa cells (Figure 3B). To investigate 
whether HOXA11-AS could also enhance invasion in 
cervical cancer cells, we performed a Matrigel invasion 
assay. Homeobox A11 antisense lncRNA overexpression 
in SiHa and ME-180 cells resulted in increased invasion 
relative to empty vector-expression cells (Figure 3C). In 
contrast, HOXA11-AS knockdown in HeLa and CaSki cells 
led to a decrease in cell invasion (Figure 3D).
Knockdown of HOXA11-AS inhibits MMP-9, 
MMP-2, and VEGF expression in cervical  
cancer cells
To explore molecular mechanisms underlying 
HOXA11-AS promotion of cell migration and invasion, 
we characterized the expression of MMP-9, MMP-2, 
Figure 1: Relative HOXA11-AS expression and its clinical significance. A. Elevated expression of HOXA11-AS in human 
cervical cancer tissues. Homeobox A11 antisense lncRNA expression was significantly higher in cervical cancer tissues (n=92) than in 
noncancerous tissues (n=30). Relative HOXA11-AS expression was determined using qRT-PCR with U6 as an internal control. Data are 
expressed as means ± SD. *P<0.05 vs. non-tumor control. B. Expression of HOXA11-AS in cervical cancer cells. Homeobox A11 antisense 
lncRNA expression was evaluated using qRT-PCR with U6 as an internal control. C. The median OS durations were 43 and 46.5 months in 
the high and low HOXA11-AS expression groups, respectively. The log-rank test indicated that the low HOXA11-AS expression group had 
a significantly longer OS than the high group (P=0.009). Five-year survival rates were 54.5% and 75.7% in the high and low HOXA11-AS 
expression groups, respectively.
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Table 1: Clinicopathological features and HOXA11-AS expression in cervical cancer patients
Variables Total (n=92) High HOXA11-AS (n=41) Low HOXA11-AS (n=51) p value
Age (years) 51.5 ± 12.7 51.9 ± 12.6 51.2 ± 10.3 0.734
Stage
 I 36 (39.1%) 15 (36.6%) 21 (41.2%) 0.23
 II 46 (50.0%) 19 (46.3%) 27 (52.9%)
 III 10 (10.9%) 7 (17.1%) 3 (5.9%)
Histology
 Squamous cell 63 (68.5%) 28 (68.3%) 35 (68.6%) 0.098
 Adenomatous 21 (22.8%) 10 (24.4%) 11 (21.6%)
 Mixed 2 (2.2%) 2 (4.9%) 0
 Small cell 5 (5.4%) 0 5 (9.8%)
 Unknown 1 (1.1%) 1 (2.4%) 0
Lymphovascular invasion 46 (50.0%) 23 (56.1%) 23 (45.1%) 0.052
Lymph node metastasis 21 (22.8%) 12 (29.3%) 9 (17.6%) 0.142
Recurrence 24 (26.1%) 13 (31.7%) 11 (21.6%) 0.194
Table 2: Univariate and multivariate analyses for various determinants in patients with cervical cancer
No. of patients
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Age, years 
(continuous) 92 0.993 (0.960-1.027) 0.692
Stage
 1 36 1 (Reference) 1 (Reference)
 2 46 0.743 (0.314-1.760) 0.5 0.650 (0.254-1.659) 0.367
 3 10 3.492 (1.258-9.691) 0.016 3.546 (1.223-10.280) 0.02
Lymphovascular 
invasion
 No 43 1 (Reference)
 Yes 46 2.118 (0.094-4.774) 0.07
Nodal metastasis
 No 71 1 (Reference) 1 (Reference)
 Yes 21 2.617 (1.210-5.662) 0.015 2.724 (1.145-6.483) 0.023
Recurrence
 No 68 1 (Reference) 1 (Reference)
 Yes 24 3.268 (1.521-7.020) 0.002 2.046 (0.862-4.857) 0.105
HOXA11-AS 
expression
 Low 51 1 (Reference) 1 (Reference)
 High 41 2.769 (1.242-6.174) 0.013 2.450 (1.079-5.561) 0.032
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and VEGF. siHOXA11-AS decreased MMP-9, MMP-
2, and VEGF expression levels in HeLa cells (Figure 
4A). siRNA-mediated knockdown of HOXA11-AS 
inhibited MMP-9, MMP-2, and VEGF protein expression 
(Figure 4B). Our findings suggest that HOXA11-AS 
promotes cervical cancer cell migration and invasion via 
upregulation of MMP-9, MMP-2, and VEGF.
HOXA11-AS knockdown reversed EMT-related 
genes in cervical cancer cells
Because the EMT is important in cell migration 
and invasion, we tested whether HOXA11-AS is required 
for EMT. We performed siRNA-mediated knockdown of 
HOXA11-AS in HeLa cells, and monitored EMT using 
real-time RT-PCR and western blot assays. Knockdown 
of HOXA11-AS resulted in an increase in E-cadherin 
expression and decreases in β-catenin and vimentin 
expression (Figures 5A–5B). In addition, the EMT-
mediating transcription factor Snail was downregulated 
in siHOXA11-AS-transfected cells, relative to its level in 
negative control siRNA (siNC) transfected cells (Figures 
5A–5B). These data suggest that dysregulation of EMT-
related genes partially explains the involvement of 
HOXA11-AS in cervical cancer cell migration and invasion.
HOXA11-AS promotes sphere formation and 
expression of stemness markers
The EMT program confers stem cell-like properties 
to normal and tumor cells [16, 20, 21]. To assess whether 
HOXA11-AS promotes CSC generation, we treated the 
Figure 2: Knockdown of HOXA11-AS inhibits the proliferation of cervical cancer cells. A. Cells were transfected with 
HOXA11-AS-specific siRNA and negative control siRNA (siNC), and knockdown efficiency was determined by qRT-PCR analysis. B. 
Knockdown of HOXA11-AS decreases cell proliferation in HeLa and CaSki cells. The proliferation of cervical cancer cells transfected with 
siHOXA11-AS and siNC was determined using the CCK-8 assay. Bars indicate means ± SD of three independent experiments. *P<0.05 
vs. siNC.
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Figure 3: Homeobox A11 antisense lncRNA promotes cell migration and invasion. A. Overexpression of HOXA11-AS in 
SiHa and ME-180 cells, analyzed using qRT-PCR. B. Wound healing assay was used to determine migration in HOXA11-AS overexpressed 
SiHa cells and siHOXA11-AS-transfected HeLa cells (×200). C. Using the Matrigel invasion chamber, overexpression of HOXA11-AS in 
SiHa and ME-180 cells increased the invasive capacity after 48 h. D. Matrigel invasion assay was used to determine invasion after 48 h 
in siHOXA11-AS-transfected HeLa and CaSki cells. Each assay was performed in triplicate. Data are mean ± SD. *P<0.05 vs. control.
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CaSki and HeLa cervical cancer cells for 5 days, and 
counted the number of cells expressing the CSC markers 
CD133+/CD44+ [22, 23]. Spheroid HeLa cells promoted an 
increase in the number of CD133+/CD44+ (Figure 6A and 
6B). We next evaluated HOXA11-AS expression in non-
spheroid and spheroid cells. Gene expression analyses in 
CaSki and HeLa cells showed that spheroid cells express 
HOXA11-AS at levels tenfold and fourfold that of control 
cells, respectively (Figure 6C).
Next, to determine whether HOXA11-AS promotes 
self-renewal of cervical cancer cells, an important 
feature of CSCs, we assayed sphere formation in CaSki 
and HeLa cells 2 days after HOXA11-AS knockdown. 
After 7 days of incubation in anchorage-independent 
conditions, the control cells presented an elevated 
number of large colonies, while the HOXA11-AS-
silenced cells formed only a few colonies of small size 
(Figure 7A). Counting of colonies revealed a reduction 
in sphere formation (Figure 7B). We counted the number 
of cells expressing the CD133+/CD44+ CSC markers. As 
expected, siHOXA11-AS-spheroid HeLa cells exhibited 
a decrease in the number of CD133+/CD44+ compared 
with the siNC-spheroid HeLa cells (Figure 7C). In order 
to verify the effectiveness of siHOXA11-AS during the 
Figure 4: Knockdown of HOXA11-AS decreases MMP-9, MMP-2, and VEGF expression in cervical cancer cells. A. 
MMP-9, MMP-2, and VEGF expression were analyzed by qRT-PCR. B. Protein lysates were obtained from siHOXA11-AS and siNC-
transfected HeLa cells 48 h post-transfection. MMP-9, MMP-2, and VEGF expression were analyzed by western blotting. C. Band 
intensities were quantified and normalized to that of β-actin. Each assay was performed in triplicate. Data are mean ± SD. *P<0.05 vs. 
siNC. **P<0.05 vs. siNC.
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sphere formation assays, we measured its expression 
7 days after siRNA treatment. Although we detected a 
slight recovery in HOXA11-AS expression, a significant 
knockdown was still observed (Figure 7D). To further 
characterize siHOXA11-AS-decreased spheres and 
determine the molecular mechanisms underlying these 
observations, we evaluated the expression of several 
stemness genes in siHOXA11-AS-spheroid HeLa cells 
using western blotting (Figure 7E). We found that the 
expression of SOX2, Oct-4, and Nanog were significantly 
downregulated in siHOXA11-AS-spheroid HeLa cells, 
relative to the corresponding expression levels in control 
cells.
Since HOXA11-AS is necessary to promote the EMT 
program (Figure 5), we evaluated the expression of EMT-
related genes using western blot analysis in siHOXA11-
AS-spheroid HeLa cells. β-Catenin, N-cadherin, and 
vimentin expression was downregulated in siHOXA11-
AS-spheroid HeLa cells, relative to the corresponding 
levels in control cells (Figure 7E). These results suggest 
that HOXA11-AS contributes to activating the genetic 
program that promotes EMT and supports the CSC 
phenotype.
Knockdown of HOXA11-AS decreases xenograft 
tumor growth in mice
To assess whether HOXA11-AS knockdown can 
decrease tumor growth in vivo, we inoculated HeLa 
cells as xenografts into nude mice (Figure 8A). Tumor 
Figure 5: Expression of HOXA11-AS knockdown on the EMT-related genes in HeLa cells. HeLa cells were transfected with 
HOXA11-AS-specific siRNA and siNC for 48 h. E-cadherin, β-catenin, Vimentin, and Snail expression were analyzed by qRT-PCR A. and 
western blotting B., C. Band intensities were quantified and normalized to that of β-actin. Each assay was performed in triplicate. Data are 
mean ± SD. *P<0.05 vs. siNC. **P<0.05 vs. siNC.
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volume and weight were measured. Mice injected with 
siHOXA11-AS-transfected cells presented significantly 
decreased tumor growth and weights compared with those 
injected with control cells (Figures 8B–8C). Homeobox 
A11 antisense lncRNA expression in tumor tissue was 
downregulated in siHOXA11-AS-transfected cells 
compared with control cells (Figure 8D). Tumor weight 
correlated with tumor volume, as determined by calipers 
(P<0.001; r2=0.935). We further evaluated tumor size 
using MRI (Figure 8E). Tumor size was strongly inhibited 
by HOXA11-AS knockdown. These findings suggested that 
HOXA11-AS promoted tumor growth in vivo and further 
supported our hypothesis that HOXA11-AS is involved in 
the pathogenesis of cervical cancer cells.
DISCUSSION
Long noncoding RNAs are protagonists in recent 
narratives of the complex mechanisms underlying 
malignant processes including tumorigenesis, drug-
resistance, and metastasis [24–26]. The present study 
investigated the molecular function and clinical 
significance of HOXA11-AS expression in cervical 
cancer cell lines and mouse xenograft models. We found 
that enhanced HOXA11-AS expression was associated 
with poor overall survival. Knockdown of HOXA11-
AS expression correlated with decreased cell growth, 
migration, and invasion in cervical cancer cells. The 
effects of HOXA11-AS on tumor progression may be 
mediated by genes involved in cell migration, invasion, 
and EMT-related genes; these genes include VEGF, MMP-
9, MMP-2, E-cadherin, β-catenin, Vimentin, and Snail. 
In addition, downregulation of HOXA11-AS expression 
inhibits EMT-related genes and the colony forming 
capacity of cervical cancer cells. Our findings indicate that 
HOXA11-AS may serve as a biomarker and therapeutic 
target for cervical cancer.
Long noncoding RNAs are transcripts of at least 
200 nucleotides without protein-coding capacity. Little is 
known about the regulatory roles of lncRNAs and their 
relevance to human disease; however, the functional 
role of small regulatory ncRNAs such as miRNAs in 
Figure 6: Sphere formation increased the CD133+/CD44+ cancer stem cell subpopulation and HOXA11-AS expression 
in cervical cancer cell lines. A. HeLa and CaSki cells were incubated for 5 days, and stained with anti-CD44 and anti-CD-133. 
Representative dot-plots are shown in B., C. Enriched populations of spheroid and non-spheroid HeLa and CaSki cells were subjected to 
qPCR analysis of HOXA11-AS. Each assay was performed in triplicate. Data are mean ± SD.
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human cancers is well established. Many lncRNAs are 
capped, spliced, and polyadenylated, like their protein-
coding counterparts [27]. Long noncoding RNAs exhibit 
tissue-specific expression patterns. The growing list of 
functionally characterized lncRNAs implies that these 
transcripts are critical to various physiological processes 
[28], and therefore, modified expression of lncRNAs may 
affect cancer development and progression [29].
The literature increasingly reports that Hox proteins 
correlate with cancer development [9, 30, 31]. Homeobox 
Figure 7: Homeobox A11 antisense lncRNA knockdown inhibited sphere formation. Representative images A. and 
quantification B. of spheres formed from CaSki and HeLa cells, previously transfected with siHOXA11-AS or siNC. Spheres were counted 
by visual inspection in light microscopy. HeLa cells were incubated for 7 days, and stained with anti-CD44 and anti-CD-133. Representative 
dot-plots are shown in C., D. qPCR was performed to evaluate the expression of HOXA11-AS on days 1 and 7 of the sphere assays. Data are 
reported as means ± SD for three independent experiments. *P<0.05 vs. siNC. E. EMT-related gene, Oct-4, SOX2, and Nanog expression 
were analyzed by western blotting.
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genes were first discovered in Drosophila melanogaster, 
and subsequently the structures of human HOX proteins 
were solved [37, 38]. Several cancers that overexpress 
HOXA11 include epithelial ovarian cancers [13, 30], 
bladder cancer [32], cervical cancer [9] and glioma [36]. 
However, there are few reports of the biology and function 
of HOXA11-AS in cervical cancer cells.
We found that HOXA11-AS expression associates 
with disease progression in cervical cancer patients; 
this lncRNA increased the proliferation, migration, 
and invasion of cervical cancer cells in vitro and in 
vivo. Long noncoding RNAs are essential for the 
regulation of chromatin structure, gene expression, 
and translational control [33]. In particular, the level of 
HOXA11 methylation efficaciously distinguishes high-
grade squamous intraepithelial lesion cells from healthy 
cells; HOXA11 is also important in the embryological 
development of the Müllerian duct in the uterine cervix 
[34]. Through HOXA11, HOXA11-AS may affect cervical 
cancer development.
In addition, we discovered that downregulation of 
HOXA11-AS expression decreases cervical cancer cell 
proliferation, migration, and invasion. Therefore, HOXA11-
AS may exert oncogenic activity in cervical cancer, and 
promote aggressive and metastatic characteristics. MMP-9 
degrades basement membrane collagen, and accordingly 
promotes tumor cell invasion and metastasis, decreasing 
survival in many types of cancer [35, 36]. Moreover, 
tumor angiogenesis is decisive in tumor growth, invasion, 
and metastasis. The angiogenic factor VEGF activates 
tumor angiogenesis, and accordingly is a major target of 
many cancer medications [37]. In our investigation, high 
expression of HOXA11-AS in cervical cancer cell induced 
cell migration and invasion through the upregulation of 
EMT-related genes, VEGF, and MMP-9. More importantly, 
downregulation of HOXA11-AS expression prevented 
Figure 8: Effect of HOXA11-AS on tumor growth in vivo. A. Images represent tumor growth in the nude mice 26 days after 
they were injected with 5 × 106 siNC or siHOXA11-AS-transfected HeLa cells (n=6 mice/group). Gross images of tumor masses from 
representative mice from each group (right panel). B. Tumor volume was calculated every 3~4 days. Data are mean ± SE (n=6). *P<0.05 
and ** P<0.001 vs. siNC. C. Tumor weight. Data are mean ± SE. D. qRT-PCR analysis of HOXA11-AS expression in tissues of resected 
tumors. E. Representative MRI imaging of mice four weeks after injection.
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EMT induction and CSCs arising. We found that HOXA11-
AS increases sphere-forming capacity. Furthermore, 
HOXA11-AS knockdown decreased expression of stemness 
genes, SOX2, Oct-4, and Nanog in cervical cancer cells. 
In addition, knockdown of HOXA11-AS downregulated 
expression of EMT-related genes. We hypothesized that 
HOXA11-AS acts as a key regulator of different signaling 
mechanisms involved in EMT/stemness establishment. 
We provided the first evidence that HOXA11-AS promotes 
CSC self-renewal and EMT in cervical cancer cells, which 
may contribute to cervical cancer growth, invasion, and 
recurrence.
The recurrence rate after radical surgery for early-
stage cervical cancer is 15–30%, and the recurrent patients 
have poor prognoses [38]. Reliable predictors of recurrence 
and progression are necessary to improve the prognoses 
of cervical cancer patients. Pelvic lymph node metastasis 
is one of the most important postoperative risk factors 
for recurrence or failure to survive. Thus, cervical cancer 
patients with metastasis in the pelvic lymph nodes require 
adjuvants such as postoperative radiotherapy [2, 36].
We show that high HOXA11-AS expression 
correlates with poor overall survival, as the advanced 
stage and nodal metastasis. Evaluation of HOXA11-AS 
expression in cervical cancer patients may predict the risk 
of progression or recurrence, thereby informing treatment 
decisions. Notwithstanding the prognostic significance 
of HOXA11-AS for tumor progression or recurrence, 
the present study’s relatively small sample size signals 
for interpretive caution. Larger prospective studies are 
necessary to validate our findings.
MATERIALS AND METHODS
Patient specimens
Included in this study were 92 female patients who 
underwent surgery between 2007 and 2014 at Yonsei 
Severance Hospital, Yonsei University. Specimens from 
patients with newly diagnosed invasive stage IA to IVB 
cervical cancer (International Federation of Gynecology 
and Obstetrics, FIGO) who had not received prior 
treatment were included in this study. Thirty samples 
of normal cervix from patients undergoing simple 
hysterectomy because of uterine leiomyomata were 
obtained as controls. This study was conducted according 
to the principles of the Declaration of Helsinki, and was 
approved by the Ethics Committee of Yonsei Severance 
Hospital. Informed consent was obtained from all patients. 
All specimens were immediately frozen in liquid nitrogen 
and stored at –80°C until RNA extraction.
Cell lines
We obtained SiHa, HeLa, CaSki, ME-180 and C33A 
human cervical cancer cell lines from the American Type 
Culture Collection (Rockville, MD). Squamous cervical 
carcinoma and HeLa cells were cultured in Dulbecco's 
Modified Eagle Medium; ME-180 and C33A cells were 
cultured in Eagle’s Minimum Essential Medium (Gibco-
BRL, Gaithersburg, MD, USA) ; CaSki cells were cultured 
in RPMI-1640 medium (Gibco-BRL). The human normal 
ovarian cancer cell line HOSE was cultured in MCDB 
105 (Sigma Aldrich, Castle Hill, Australia) medium. 
Culture media were supplemented with 10% (v/v) fetal 
bovine serum and penicillin/streptomycin. All cell lines 
were maintained at 37°C in a humidified incubator with 
5% CO2.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted using TRIzol® reagent 
(Invitrogen Corp., Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Two micrograms of total RNA 
were reverse transcribed into first-strand cDNA using a 
reverse transcription reagent kit (Invitrogen). The cDNA 
template was amplified by qRT-PCR, using the SYBR® 
Green Real-time PCR Kit (TOYOBO Co. Ltd, Osaka, 
Japan). qRT-PCR was performed on the ABI StepOnePlus 
Real-Time PCR System (Applied Biosystems, Foster City, 
CA, USA). All quantifications were performed with U6 
as the internal standard. Relative gene expression was 
analyzed using the 2–ΔΔCT method, and the results were 
expressed as extent of change with respect to control 
values. qRT-PCR experiments were replicated at least 
three times. Primers used for PCR reactions are shown in 
Table S1.
Small interfering RNA (siRNA) transfection
Homeobox A11 antisense lncRNA siRNA 
(siHOXA11-AS) and negative control siRNA (siNC) were 
purchased from Genolution (Genolution Pharmaceuticals 
Inc., Seoul, Korea). Cells (5×104 cells/well) were seeded 
into 6-well plates and transfected with 10 nM siRNA in 
phosphate-buffered saline (PBS), using the G-Fectin 
Kit (Genolution Pharmaceuticals), according to the 
manufacturer’s protocol. These siRNA-transfected cells 
were used in the in vitro assays 48 h post-transfection. The 
target sequences for HOXA11-AS siRNAs were as follows: 
siRNA, 5′-CGGAAUAUCGGAAUAAAGUUU-3′. The 
experiments were repeated at least three times.
Plasmid constructs and the generation of stable 
cell lines
Full-length human HOXA11-AS transcript cDNA 
was amplified by PCR and inserted into the pLenti6/V5-
D-TOPO vector, according to the ViraPower™ Lentiviral 
Expression Systems (Invitrogen) protocol. The plasmid 
was transfected into 293FT cells for packaging, and the 
resultant lentivirus was used to infect the desired cell lines. 
The selection of HOXA11-AS stably transfected cells was 
performed in medium containing blasticidin (Invitrogen).
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Cell proliferation assay
Cell proliferation was evaluated using the Cell 
Counting Kit-8 (CCK-8) assay (Dojindo Laboratories, 
Kumamoto, Japan). Cells (2 × 103 cells/well) were seeded 
into 96-well flat-bottomed plates in 100 μL of complete 
medium. The cells were incubated overnight to allow 
for cell attachment and recovery, and were subsequently 
transfected with siNC or siHOXA11-AS for 24, 48, 72, or 
96 h. An aliquot of 10 μL of CCK-8 solution was added 
to each well and incubated for 2 h. The absorbance was 
measured at 450 nm to calculate the number of viable 
cells in each well. Three independent experiments were 
performed in triplicate.
Matrigel invasion assay
The Matrigel invasion assay was performed using 
the BD Biocoat Matrigel Invasion Chamber (pore size: 
8 mm, 24-well; BD Biosciences, Bedford, MA, USA), 
according to the manufacturer's protocol. Briefly, 5 × 104 
cells were plated in the upper chamber on serum-free 
medium, and complete medium was added to the bottom 
chamber. The Matrigel invasion chamber was incubated 
for 48 h at 37°C under 5% CO2. Non-invading cells 
were removed from the upper chamber using cotton-
tipped swabs. Cells that had invaded through the pores 
onto the lower side of the filter were stained (Diff Quik, 
Sysmes, Kobe, Japan), and these cells were counted using 
a hemocytometer. The assay was replicated at least three 
times.
Wound healing migration assay
Cell migration was assessed by wound healing 
assay. In brief, 5 × 105 cells were seeded into 6-well 
culture plates with serum-containing medium and allowed 
to grow to 90% confluency in complete medium. The 
serum-containing medium was removed, and cells were 
serum starved for 24 h. When the cell density reached 
~ 100% confluence, an artificial homogenous wound was 
created by scratching the monolayer with a sterile 200-
μL pipette tip. After scratching, the cells were washed 
with serum-free medium. Images of cells migrating 
into the wound were captured at 0, 24, and 48 h using a 
microscope. The assay was performed in triplicate.
Self-renewal assay
CaSki and HeLa cells (1 cell/μL in SFM) were 
seeded at 100 μL/well in 96-well plates for seven days. 
The total number of spheres in each well was counted 
under a microscope. The cells were dissociated, stained 
with Trypan blue (Amresco Inc., Solon, OH), and counted 
under a microscope to determine the total cell number. All 
experiments were done in triplicate.
Fluorescence-activated cell sorting analysis
Cells were washed with PBS and fixed with PBS 
supplemented with 3% paraformaldehyde (10 min, 4°C), 
and incubated with one of the following four antibody 
treatments: no treatment; anti-CD44-APC (clone-IM7, 
eBioscience); anti-CD133-PE (clone-AC133, Miltenyi 
Biotec., San Diego, CA, USA); or both anti-CD133-PE 
and anti-CD44-APC. Cell staining was in accordance with 
manufacturer's instructions. FACS analysis was carried out 
with a FACScanto apparatus (Becton Dickinson).
Western blot analysis
Proteins were extracted with RIPA buffer (Thermo 
Fisher Scientific Inc. Waltham, MA USA). Protein 
concentrations were measured using the Pierce BCA 
Protein assay kit (Thermo Fisher Scientific). After 
boiling with 2× sample buffer, proteins were resolved 
on 10% SDS–polyacrylamide gels, and transferred 
electrophoretically to polyvinylidene difluoride 
membranes (Millipore, Billerica, MA, USA). Membranes 
were blocked with 5% non-fat dried milk in 1× Tris-
buffered saline containing 0.1% Tween 20 (pH 7.6) 
at room temperature for 1 h, and were subsequently 
incubated with primary antibody at 4°C overnight under 
constant agitation. The primary antibodies included rabbit 
anti-human VEGF (1:500 dilution; Abcam, Cambridge, 
MA, USA), rabbit anti-human MMP-2 (1:500 dilution; 
Abcam), rabbit anti-human MMP-9 (1:1000 dilution; 
Cell Signaling, Beverly, MA, USA), rabbit anti-human 
E-cadherin (1:1000 dilution; Cell Signaling), rabbit anti-
human β-catenin (1:1000 dilution; Cell Signaling), mouse 
anti-human Vimentin (1:1000 dilution; Sigma, St. Louis, 
MO, USA), mouse anti-human Snail (1:1000 dilution; Cell 
Signaling), rabbit anti-human SOX-2 (1:1000 dilution; 
Cell Signaling), rabbit anti-human Nanog (1:1000 dilution; 
Cell Signaling), rabbit anti-human Oct-4 (1:1000 dilution; 
Cell Signaling), and mouse anti-human β-actin antibody 
(1:5000 dilution; Sigma). Proteins were visualized 
using an enhanced chemiluminescence system (ECL™; 
Amersham, Little Chalfont, UK), and band intensities 
were quantified using the Luminescent Image Analyzer 
(LAS-4000 mini, Fujifilm, Uppsala, Sweden).
Xenografts in mice
BALB/c mice (n=12, 5–6 weeks of age, Orient 
Bio, Seongnam, Korea) were kept in aseptic, constant 
temperature and humidity, conditions (Yonsei Medical 
University protocol). Each mouse received a 150-
μL subcutaneous dorsal scapula injection of HeLa 
cell suspension. The size of the tumor was measured 
twice weekly with calipers, and the tumor volume was 
determined using the simplified formula for a rotational 
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ellipsoid (length × width² × 0.5). Each tumor was 
harvested at 30 days post-treatment.
Magnetic resonance (MR) imaging in mice
A Bruker Biospec 94/24 USR (9.4T) small animal 
scanner (35-mm diameter birdcage coil, Bruker BioSpin 
MRI, Ettlingen, Germany) was used to obtain the 
MR images. During the MR experiments, mice were 
immobilized by placement in a custom-built cradle. T2-
weighted images were obtained at the beginning of each 
imaging session for accurate positioning of the animal 
inside the magnet bore. The T2-weighted images were 
acquired using the rapid acquisition setting. An O2/N2O 
mixture (1:1) with 1.5% isoflurane, at a 0.7 L/min flow 
rate, was used for anesthesia. An air pillow was used to 
monitor respiration. Circulating warm water was used to 
maintain mouse body temperature within acceptable limits.
Comparison of clinical outcomes and survival
Low HOXA11-AS expression was defined as 
expression less than 10-fold. Ten-fold or more than 10-
fold expression of HOXA11-AS was considered high 
HOXA11-AS. Survival rate and clinical outcomes were 
analyzed and compared between the two groups. Overall 
survival was defined as the period in months between the 
date of diagnosis and the date of death or last contact.
Statistical analysis
IBM SPSS version 20 for Windows (SPSS Inc., 
Chicago, IL, USA) was used for the statistical analysis. 
The Kolmogorov–Smirnov test was used to verify 
standard normal distributional assumptions. Statistical 
significance was determined using Fisher’s exact test, 
Pearson’s chi square test, and Student’s t test. Univariate 
and multivariate analysis using the Cox proportional 
hazards model was performed to assess the influence of 
various prognostic factors on survival. Survival outcomes 
were determined through a Kaplan–Meier survival 
analysis. Mean differences were considered significant 
when P<0.05. Results are shown as mean ± SD.
ACKNOWLEDGMENTS
This research was supported by the Basic 
Science Research Program through the National 
Research Foundation of Korea (NRF) funded by 
the Ministry of Science, ICT & Future Planning 
(2015R1A2A2A01008162; 2015R1C1A2A01053516).
CONFLICTS OF INTEREST
All authors declare that they have no conflicts of 
interest to report.
REFERENCES
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, 
Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 
2015; 65: 87-108. doi: 10.3322/caac.21262.
2. Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, 
Hongo A, Hiramatsu Y. Prognostic factors in stage IB-IIB 
cervical adenocarcinoma patients treated with radical 
hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 
2010; 101: 413-7. doi: 10.1002/jso.21499.
3. Noordhuis MG, Fehrmann RS, Wisman GB, Nijhuis ER, 
van Zanden JJ, Moerland PD, Ver Loren van Themaat E, 
Volders HH, Kok M, ten Hoor KA, Hollema H, de Vries 
EG, de Bock GH, et al. Involvement of the TGF-beta and 
beta-catenin pathways in pelvic lymph node metastasis in 
early-stage cervical cancer. Clin Cancer Res. 2011; 17: 
1317-30. doi: 10.1158/1078-0432.ccr-10-2320.
4. Perez DS, Hoage TR, Pritchett JR, Ducharme-Smith AL, 
Halling ML, Ganapathiraju SC, Streng PS, Smith DI. Long, 
abundantly expressed non-coding transcripts are altered in 
cancer. Hum Mol Genet. 2008; 17: 642-55. doi: 10.1093/
hmg/ddm336.
5. Guttman M, Donaghey J, Carey BW, Garber M, Grenier 
JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang 
X, Amit I, Meissner A, et al. lincRNAs act in the circuitry 
controlling pluripotency and differentiation. Nature. 2011; 
477: 295-300. doi: 10.1038/nature10398.
6. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, 
Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, 
Segal E, Chang HY. Functional demarcation of active 
and silent chromatin domains in human HOX loci by 
noncoding RNAs. Cell. 2007; 129: 1311-23. doi: 10.1016/j.
cell.2007.05.022.
7. Ponting CP, Oliver PL, Reik W. Evolution and functions 
of long noncoding RNAs. Cell. 2009; 136: 629-41. doi: 
10.1016/j.cell.2009.02.006.
8. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant 
GD, Horlings HM, Shah N, Umbricht C, Wang P, Wang 
Y, Kong B, Langerod A, et al. Extensive and coordinated 
transcription of noncoding RNAs within cell-cycle 
promoters. Nat Genet. 2011; 43: 621-9. doi: 10.1038/
ng.848.
9. Chen J, Fu Z, Ji C, Gu P, Xu P, Yu N, Kan Y, Wu X, Shen R, 
Shen Y. Systematic gene microarray analysis of the lncRNA 
expression profiles in human uterine cervix carcinoma. 
Biomed Pharmacother. 2015; 72: 83-90. doi: 10.1016/j.
biopha.2015.04.010.
10. Mainguy G, Koster J, Woltering J, Jansen H, Durston A. 
Extensive polycistronism and antisense transcription in the 
mammalian Hox clusters. PLoS One. 2007; 2: e356. doi: 
10.1371/journal.pone.0000356.
11. Krumlauf R. Hox genes in vertebrate development. Cell. 
1994; 78: 191-201. doi: 
12. Chau YM, Pando S, Taylor HS. HOXA11 silencing and 
endogenous HOXA11 antisense ribonucleic acid in the 
Oncotarget83015www.impactjournals.com/oncotarget
uterine endometrium. J Clin Endocrinol Metab. 2002; 87: 
2674-80. doi: 10.1210/jcem.87.6.8527.
13. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, 
Lechner M, Jacobs IJ, Widschwendter M. HOXA11 DNA 
methylation--a novel prognostic biomarker in ovarian 
cancer. Int J Cancer. 2008; 123: 725-9. doi: 10.1002/
ijc.23563.
14. Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y, Chang AE, 
Wicha MS. Concise Review: Targeting Cancer Stem Cells 
Using Immunologic Approaches. Stem Cells. 2015; 33: 
2085-92. doi: 10.1002/stem.2039.
15. Dean M, Fojo T, Bates S. Tumour stem cells and drug 
resistance. Nat Rev Cancer. 2005; 5: 275-84. doi: 10.1038/
nrc1590.
16. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou 
AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, 
Campbell LL, Polyak K, Brisken C, et al. The epithelial-
mesenchymal transition generates cells with properties 
of stem cells. Cell. 2008; 133: 704-15. doi: 10.1016/j.
cell.2008.03.027.
17. Lopez J, Poitevin A, Mendoza-Martinez V, Perez-Plasencia 
C, Garcia-Carranca A. Cancer-initiating cells derived from 
established cervical cell lines exhibit stem-cell markers and 
increased radioresistance. BMC Cancer. 2012; 12: 48. doi: 
10.1186/1471-2407-12-48.
18. Liu XF, Yang WT, Xu R, Liu JT, Zheng PS. Cervical cancer 
cells with positive Sox2 expression exhibit the properties 
of cancer stem cells. PLoS One. 2014; 9: e87092. doi: 
10.1371/journal.pone.0087092.
19. Liu CT, Xin Y, Tong CY, Li B, Bao HL, Zhang CY, Wang 
XH. Production of interleukin4 in CD133+ cervical cancer 
stem cells promotes resistance to apoptosis and initiates 
tumor growth. Mol Med Rep. 2016; 13: 5068-76. doi: 
10.3892/mmr.2016.5195.
20. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, 
Puisieux A. Generation of breast cancer stem cells through 
epithelial-mesenchymal transition. PLoS One. 2008; 3: 
e2888. doi: 10.1371/journal.pone.0002888.
21. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu 
WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D, 
et al. p53 regulates epithelial-mesenchymal transition and 
stem cell properties through modulating miRNAs. Nat Cell 
Biol. 2011; 13: 317-23. doi: 10.1038/ncb2173.
22. Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, 
Tanaka F, Mimori K, Kamohara Y, Inoue H, Mori M. 
CD133+CD44+ population efficiently enriches colon cancer 
initiating cells. Ann Surg Oncol. 2008; 15: 2927-33. doi: 
10.1245/s10434-008-0074-0.
23. Ferrand A, Sandrin MS, Shulkes A, Baldwin GS. Expression 
of gastrin precursors by CD133-positive colorectal cancer 
cells is crucial for tumour growth. Biochim Biophys Acta. 
2009; 1793: 477-88. doi: 10.1016/j.bbamcr.2009.01.004.
24. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, 
Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, 
Brzoska P, Kong B, et al. Long non-coding RNA HOTAIR 
reprograms chromatin state to promote cancer metastasis. 
Nature. 2010; 464: 1071-6. doi: 10.1038/nature08975.
25. Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, Yan X, 
Ye B, Li C, Xia P, Zhang G, Tian Y, Chen R, et al. The 
long noncoding RNA lncTCF7 promotes self-renewal of 
human liver cancer stem cells through activation of Wnt 
signaling. Cell Stem Cell. 2015; 16: 413-25. doi: 10.1016/j.
stem.2015.03.003.
26. Kim HJ, Lee DW, Yim GW, Nam EJ, Kim S, Kim SW, Kim 
YT. Long non-coding RNA HOTAIR is associated with 
human cervical cancer progression. Int J Oncol. 2015; 46: 
521-30. doi: 10.3892/ijo.2014.2758.
27. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, 
Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius 
R, Shimokawa K, Bajic VB, et al. The transcriptional 
landscape of the mammalian genome. Science. 2005; 309: 
1559-63. doi: 10.1126/science.1112014.
28. Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce 
SJ, Gardiner BB, Askarian-Amiri ME, Ru K, Solda G, 
Simons C, Sunkin SM, Crowe ML, Grimmond SM, et 
al. Long noncoding RNAs in mouse embryonic stem cell 
pluripotency and differentiation. Genome Res. 2008; 18: 
1433-45. doi: 10.1101/gr.078378.108.
29. Hall PA, Russell SH. New perspectives on neoplasia and the 
RNA world. Hematol Oncol. 2005; 23: 49-53. doi: 10.1002/
hon.748.
30. Richards EJ, Permuth-Wey J, Li Y, Chen YA, Coppola 
D, Reid BM, Lin HY, Teer JK, Berchuck A, Birrer MJ, 
Lawrenson K, Monteiro AN, Schildkraut JM, et al. A 
functional variant in HOXA11-AS, a novel long non-coding 
RNA, inhibits the oncogenic phenotype of epithelial ovarian 
cancer. Oncotarget. 2015; 6: 34745-57. doi: 10.18632/
oncotarget.5784.
31. Wang Q, Zhang J, Liu Y, Zhang W, Zhou J, Duan R, Pu 
P, Kang C, Han L. A novel cell cycle-associated lncRNA, 
HOXA11-AS, is transcribed from the 5-prime end of the 
HOXA transcript and is a biomarker of progression in 
glioma. Cancer Lett. 2016; 373: 251-9. doi: 10.1016/j.
canlet.2016.01.039.
32. Luo H, Zhao X, Wan X, Huang S, Wu D. Gene microarray 
analysis of the lncRNA expression profile in human 
urothelial carcinoma of the bladder. Int J Clin Exp Med. 
2014; 7: 1244-54. doi: 
33. Morris KV, Vogt PK. Long antisense non-coding RNAs 
and their role in transcription and oncogenesis. Cell Cycle. 
2010; 9: 2544-7. doi: 10.4161/cc.9.13.12145.
34. Apostolidou S, Hadwin R, Burnell M, Jones A, Baff D, 
Pyndiah N, Mould T, Jacobs IJ, Beddows S, Kocjan G, 
Widschwendter M. DNA methylation analysis in liquid-
based cytology for cervical cancer screening. Int J Cancer. 
2009; 125: 2995-3002. doi: 10.1002/ijc.24745.
Oncotarget83016www.impactjournals.com/oncotarget
35. Curran S, Murray GI. Matrix metalloproteinases: molecular 
aspects of their roles in tumour invasion and metastasis. Eur 
J Cancer. 2000; 36: 1621-30. doi: 
36. Biewenga P, van der Velden J, Mol BW, Stalpers LJ, 
Schilthuis MS, van der Steeg JW, Burger MP, Buist MR. 
Prognostic model for survival in patients with early stage 
cervical cancer. Cancer. 2011; 117: 768-76. doi: 10.1002/
cncr.25658.
37. Burger RA. Role of vascular endothelial growth factor 
inhibitors in the treatment of gynecologic malignancies. 
J Gynecol Oncol. 2010; 21: 3-11. doi: 10.3802/
jgo.2010.21.1.3.
38. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman 
WT, Major F. Prospective surgical-pathological study of 
disease-free interval in patients with stage IB squamous cell 
carcinoma of the cervix: a Gynecologic Oncology Group 
study. Gynecol Oncol. 1990; 38: 352-7. doi:
